Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Regulatory  ·  Weekly Digest - 10 October to 16 October 2026
Iza-Bren combination with radiotherapy received NMPA clinical trial approval for HNSCC

Weekly Digest – October 2026 Weekly Digest – October 2026 15 October 2026: Adlai Nortye partnered with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximab Adlai Nortye has entered clinical trial collaboration and supply agreements with Eli […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 10 October to 16 October 2026
SYS6062 ADC received clinical trial approval in China

Weekly Digest – October 2026 Weekly Digest – October 2026 15 October 2026: SYS6062 ADC received clinical trial approval in China CSPC Pharmaceutical Group announced that SYS6062, its investigational antibody-drug conjugate, has received approval from China’s National Medical Products Administration […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 10 October to 16 October 2026
DR30206 fusion protein received China IND approval for combination therapy in HNSCC

Weekly Digest – October 2026 Weekly Digest – October 2026 12 October 2026: DR30206 fusion protein received China IND approval for combination therapy in HNSCC Huadong Medicine’s DR30206, an antibody fusion protein has received China NMPA approval to initiate a […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 10 October to 16 October 2026
MacroGenics dosed the first patient in the phase 1 trial of MGC030 for advanced Solid tumors

Weekly Digest – October 2026 Weekly Digest – October 2026 15 October 2026: MacroGenics dosed the first patient in the phase 1 trial of MGC030 for advanced Solid tumors MacroGenics announced that the first patient has been dosed in the […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 10 October to 16 October 2026
Alentis and PinotBio partnered to develop next-generation CLDN1-targeting ADCs

Weekly Digest – October 2026 Weekly Digest – October 2026 14 October 2026: Alentis and PinotBio partnered to develop next-generation CLDN1-targeting ADCs Alentis Therapeutics and PinotBio have entered into a research collaboration and licensing agreement to develop next-generation claudin-1-targeted antibody–drug […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 10 October to 16 October 2026
Adlai Nortye partnered with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximab

Weekly Digest – October 2026 Weekly Digest – October 2026 15 October 2026: Adlai Nortye partnered with Lilly and Merck KGaA to evaluate AN4035 in combination with cetuximab Adlai Nortye has entered clinical trial collaboration and supply agreements with Eli […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 03 October to 09 October 2026
Enhertu approved in China for HER2-positive early Breast cancer with residual disease

Weekly Digest – October 2026 Weekly Digest – October 2026 08 October 2026: Enhertu approved in China for HER2-positive early Breast cancer with residual disease Daiichi Sankyo and AstraZeneca announced that Enhertu has been approved in China as adjuvant treatment […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 03 October to 09 October 2026
Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

Weekly Digest – October 2026 Weekly Digest – October 2026 08 October 2026: Datroway approved in China for metastatic TNBC ineligible for PD-1/PD-L1 inhibitors Daiichi Sankyo and AstraZeneca announced that Datroway has been approved in China for adults with unresectable […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 03 October to 09 October 2026
AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC

Weekly Digest – October 2026 Weekly Digest – October 2026 07 October 2026: AbbVie’s Temab-A receives FDA Breakthrough Therapy Designations for CRC and NSCLC AbbVie announced that the U.S. FDA has granted two Breakthrough Therapy Designations to Telisotuzumab adizutecan, its […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 03 October to 09 October 2026
[²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors

Weekly Digest – October 2026 Weekly Digest – October 2026 08 October 2026: [²¹²Pb]PSV359 receives FDA Fast Track Designation for FAP-positive solitary fibrous tumors Perspective Therapeutics has received U.S. FDA Fast Track Designation for [²¹²Pb]PSV359 for adults with locally advanced […]

by Sandhya Ramalingam

Continue Reading
‹ Previous12345678Next ›Last »
Page 4 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id